�ESBATech AG, a preeminent developer of antibody fragment therapeutics,
announced that the company has successfully accomplished its Phase I clinical
study of the company's lead product candidate, ESBA105, in ophthalmic
indications. In April 2008, ESBATech initiated the Phase I study designed to
evaluate the safety, tolerability and pharmacokinetic profile of ESBA105,
when delivered locally via eye drops in healthy volunteers. This run was
conducted as a single and repeated dose escalation sketch in Switzerland.
ESBA105 is a single-chain antibody fragment directed against TNF-alpha, and
it is being developed initially for ophthalmic indications. Several
additional clinical studies are in the
